Literature DB >> 18663359

PRIMA-1MET induces mitochondrial apoptosis through activation of caspase-2.

J Shen1, H Vakifahmetoglu, H Stridh, B Zhivotovsky, K G Wiman.   

Abstract

p53 mutations occur frequently in human tumors. The low-molecular-weight compound PRIMA-1(MET) reactivates mutant p53, induces apoptosis in human tumor cells and inhibits tumor xenograft growth in vivo. Here, we show that PRIMA-1(MET) induces mutant p53-dependent mitochondria-mediated apoptosis through activation of caspase-2 with subsequent cytochrome c release and further activation of downstream caspase-9 and caspase-3. Inhibition of caspase-2 by a selective inhibitor and/or siRNA prevents cytochrome c release on PRIMA-1(MET) treatment and causes a significant reduction in PRIMA-1(MET)-induced cell death. Our findings highlight a chain of cellular events triggered by PRIMA-1(MET) that lead to apoptotic cell death. This should facilitate further development and optimization of efficient PRIMA-1(MET)-based anticancer drugs.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18663359     DOI: 10.1038/onc.2008.249

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  23 in total

Review 1.  Translational approaches targeting the p53 pathway for anti-cancer therapy.

Authors:  Frank Essmann; Klaus Schulze-Osthoff
Journal:  Br J Pharmacol       Date:  2012-01       Impact factor: 8.739

2.  The effect of adenovirus-mediated gene expression of FHIT in small cell lung cancer cells.

Authors:  Roza Zandi; Kai Xu; Hans S Poulsen; Jack A Roth; Lin Ji
Journal:  Cancer Invest       Date:  2011-12       Impact factor: 2.176

Review 3.  p53-based cancer therapy.

Authors:  David P Lane; Chit Fang Cheok; Sonia Lain
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-05-12       Impact factor: 10.005

Review 4.  Targeting the p53 signaling pathway in cancer therapy - the promises, challenges and perils.

Authors:  Alexander H Stegh
Journal:  Expert Opin Ther Targets       Date:  2012-01-12       Impact factor: 6.902

Review 5.  P53 mutations in colorectal cancer - molecular pathogenesis and pharmacological reactivation.

Authors:  Xiao-Lan Li; Jianbiao Zhou; Zhi-Rong Chen; Wee-Joo Chng
Journal:  World J Gastroenterol       Date:  2015-01-07       Impact factor: 5.742

Review 6.  Pharmacological activation of p53 in cancer cells.

Authors:  Mohammad Athar; Craig A Elmets; Levy Kopelovich
Journal:  Curr Pharm Des       Date:  2011       Impact factor: 3.116

7.  Identification of BIRC6 as a novel intervention target for neuroblastoma therapy.

Authors:  Fieke Lamers; Linda Schild; Jan Koster; Frank Speleman; Ingrid Øra; Ellen M Westerhout; Peter van Sluis; Rogier Versteeg; Huib N Caron; Jan J Molenaar
Journal:  BMC Cancer       Date:  2012-07-12       Impact factor: 4.430

8.  2-Sulfonylpyrimidines: Mild alkylating agents with anticancer activity toward p53-compromised cells.

Authors:  Matthias R Bauer; Andreas C Joerger; Alan R Fersht
Journal:  Proc Natl Acad Sci U S A       Date:  2016-08-22       Impact factor: 11.205

9.  PRIMA-1 increases cisplatin sensitivity in chemoresistant ovarian cancer cells with p53 mutation: a requirement for Akt down-regulation.

Authors:  Noriko Kobayashi; Mohammadreza Abedini; Noriaki Sakuragi; Benjamin K Tsang
Journal:  J Ovarian Res       Date:  2013-01-26       Impact factor: 4.234

10.  Prima-1 induces apoptosis in bladder cancer cell lines by activating p53.

Authors:  Camila B Piantino; Sabrina T Reis; Nayara I Viana; Iran A Silva; Denis R Morais; Alberto A Antunes; Nelson Dip; Miguel Srougi; Katia R Leite
Journal:  Clinics (Sao Paulo)       Date:  2013       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.